

A novel GFRA1 agonist, JW0061 development for androgenic alopecia treatment

JW Pharmaceutical



OTHERS	Preclinical
Product Type	Small molecule
Indication	Androgenetic Alopecia (AGA)
Target	GFRA1 (GDNF Family Receptor Alpha 1)
MoA(Mechanism of Action)	Wnt/ β -catenin signal activator / GFRA1 agonist
Competitiveness	<ul style="list-style-type: none"> • Novel mode of action directly promoting dermal papilla in hair follicles. • New treatment option for female patients with hair loss who are not accessible to 5-α reductase inhibitors such as finasteride and dutasteride. • Treatment option for non-androgenic male patients with female-type baldness (F-type) or senescent alopecia. • Avoiding the safety issues on 5-α reductase inhibitors.
Development Stage	Preclinical
Route of Administration	Topical administration